The emerging field of cell and gene therapy (CGT) has spent its brief history proving that diseases once deemed untreatable can be tackled, and in some cases cured. Yet, according to Alexander Seyf, CEO and founder of Act for Hope, the industry now faces a different test: whether the complex network of stakeholders that supports each therapy can work together efficiently enough to reach the millions of patients who need them.
Seyf argues that CGT differs fundamentally from conventional drugs because its delivery relies on a tightly linked chain that spans patient identification, starting‑material collection, manufacturing, testing, release, logistics, treatment and long‑term follow‑up. That chain involves hospitals, manufacturers, contract development and manufacturing organizations, technology suppliers, regulators, payers, academics and patients – no single entity controls the entire journey. "Collaboration is not just desirable, it is foundational," he said.
Industry leaders have long focused on expanding manufacturing capacity, but Seyf warns that without parallel growth in collaborative infrastructure, scale‑up will be hampered by duplicated work, manual handoffs and incompatible data systems. He stresses that the goal is not to standardise the underlying science, but to harmonise interfaces and processes where competition offers no advantage, allowing the ecosystem to function as a unified whole.
Act for Hope is positioning itself as a neutral convenor to drive that harmonisation. Its agenda includes developing shared standards, interoperable digital platforms, responsible data‑exchange frameworks and permissioned benchmarking tools that let organisations tackle common bottlenecks without surrendering proprietary technology or intellectual property.
Two pilot projects illustrate the approach. First, a clinical‑trial portal designed to make advanced‑therapy studies easier for patients and physicians to discover and navigate. Second, an initiatives hub – a patient‑access portal intended to streamline communication among the many parties that move a therapy from the lab to the bedside. Both are meant to reduce the friction that currently slows patient access, even as manufacturing output rises.
While technology, automation and artificial intelligence will play a role in linking systems, Seyf cautions that technology alone cannot resolve organisational fragmentation. "Technology can connect systems. Collaboration connects people, organisations and purpose," he said, adding that both are required for the next chapter of CGT.
For Seyf, the ultimate metric of success will not be the number of therapies approved or factories built, but whether the expanding CGT ecosystem can translate scientific breakthroughs into real‑world treatments for patients in need. He says that achievement would make collaboration the defining piece of infrastructure for the field’s future.